SCHEMBL592144

SCHEMBL592144

CCOC(=O)/C=C/c1ccnc2ccc(OC)cc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.67
MAPK1 P28482 1/20 0.67
NPSR1 Q6W5P4 1/20 0.67
LMNA P02545 1/20 0.52
CYP1A2 P05177 2/20 0.49
MTNR1A P48039 3/20 0.48
MTNR1B P49286 3/20 0.48
CCNC P24863 1/20 0.46
CDK8 P49336 1/20 0.46
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
FDPS P14324 1/20 0.44
PDE4B Q07343 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL592145 1.00 KDM4E (0.67) KDM4EMAPK1NPSR1LMNACYP1A2
SCHEMBL592288 0.83 KDM4E (0.80) KDM4EMAPK1NPSR1LMNACYP1A2
SCHEMBL592287 0.83 KDM4E (0.80) KDM4EMAPK1NPSR1LMNACYP1A2
SCHEMBL13652283 0.82 MAPT (0.48) KDM4EMAPK1NPSR1LMNAALDH1A1
SCHEMBL2387138 0.82 ALDH1A1 (0.53) KDM4EMAPK1NPSR1LMNACYP1A2
SCHEMBL7207768 0.82 ALDH1A1 (0.53) KDM4EMAPK1NPSR1LMNACYP1A2
SCHEMBL3375911 0.81 KDM4E (0.44) KDM4EMAPK1NPSR1CYP1A2CCNC
SCHEMBL3375908 0.81 KDM4E (0.44) KDM4EMAPK1NPSR1CYP1A2CCNC
SCHEMBL25288435 0.80 HDAC8 (0.58) KDM4EALDH1A1FDPSMAOBHDAC8
SCHEMBL7205018 0.80 HDAC8 (0.58) KDM4EALDH1A1FDPSMAOBHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2146987-B1 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2015-12-02 EP disclosed
US-8114867-B2 Oxazolidinone antibiotic derivatives ACTELION PHARMACEUTICALS LTD (CH) 2012-02-14 US disclosed
US-20100137290-A1 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-06-03 US disclosed
EP-2146987-A2 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-01-27 EP disclosed
WO-2008126024-A2 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137290-A1 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES OXA1L, XDH, CCNY KDM4E 1842/4885MAPK1 2466/4885NPSR1 1838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.